NovoRapid

NovoRapid

insulin aspart

Manufacturer:

Novo Nordisk

Distributor:

DKSH
Concise Prescribing Info
Contents
Insulin aspart
Indications/Uses
DM in adults, adolescent & childn ≥1 yr.
Dosage/Direction for Use
SC Individualized dosage, used in combination w/ intermediate-acting or long-acting insulin at least once daily. Adult & childn ≥1 yr Individual insulin requirement: Usually between 0.5 & 1 U/kg/day. May be used for continuous SC insulin infusion or if necessary, for IV use.
Administration
Should be taken with food: Administer immediately before meals or soon after meals.
Contraindications
Special Precautions
Seek physician's advice before travelling between different time zones. May lead to hyperglycaemia & diabetic ketoacidosis w/ inadequate dosing or discontinuation of treatment in type 1 DM especially in childn. Hypoglycemia may occur w/ omission of a meal or unplanned, strenuous physical exercise. Change in usual warning symptoms of hypoglycaemia w/ intensified insulin therapy. Transfer to another type of insulin products should be done under strict medical supervision. Consider rapid onset of action in concomitant diseases or medication where delayed absorption of food might be expected. May require changes in insulin dose in patients w/ concomitant diseases of kidney, liver, or those affecting the adrenal, pituitary, or thyroid gland. Less pronounced early warning symptom of hypoglycaemia when transferring from different types of insulin products. Inj site reactions may occur. Especially in childn, match insulin doses (especially in basal-bolus regimens) w/ food intake, physical activities & current blood glucose level in order to minimise the risk of hypoglycaemia. Concomitant use w/ thiazolidinediones. Rarely, formation of insulin Ab may form; adjust dose to correct tendency for hyper- or hypoglycaemia. May impair the ability to drive & operate machines. Pregnancy & lactation. Childn <1 yr.
Adverse Reactions
Hypoglycaemia. Urticaria, rash, eruptions; refraction disorders; diabetic retinopathy; lipodystrophy; inj site reactions; oedema.
Drug Interactions
May cause CHF in concomitant use w/ thiazolidinediones. May reduce insulin requirement w/ oral antidiabetics, MAOIs, β-blockers, ACEIs, salicylates, anabolic steroids & sulfonamides. May increase insulin requirement w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. Decreased or increased insulin requirement w/ octreotide/lanreotide. Masked hypoglycaemic symptoms w/ β-blockers. Intensified or reduced insulin hypoglycaemic effects w/ alcohol.
ATC Classification
A10AB05 - insulin aspart ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
NovoRapid FlexPen 100 u/mL
Packing/Price
3 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in